Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lilly files six lawsuits in bid to shut down 'black market' for retatrutide

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

Lilly has filed six lawsuits targeting sellers of illicit versions of retatrutide, a highly anticipated obesity drug, ahead of its formal approval filing to protect its market.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Aug 2026 and 13 Aug 2026.

◆ ◆ The Wire takeaway

You face rising enforcement risks around unauthorised versions of breakthrough drugs like retatrutide. Targeting counterfeit sellers creates fresh market clarity that you can use to justify premium pricing and safer supply chains.

◆ Coverage

2 sources · first reported 12 Aug 2026 · latest 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotechobesity-drugspharma-litigationdrug-approvalblack-market